Your browser doesn't support javascript.
loading
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Aragón-Herrera, Alana; Feijóo-Bandín, Sandra; Otero Santiago, Manuel; Barral, Luis; Campos-Toimil, Manuel; Gil-Longo, José; Costa Pereira, Thiago M; García-Caballero, Tomás; Rodríguez-Segade, Santiago; Rodríguez, Javier; Tarazón, Estefanía; Roselló-Lletí, Esther; Portolés, Manuel; Gualillo, Oreste; González-Juanatey, José Ramón; Lago, Francisca.
Afiliação
  • Aragón-Herrera A; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago/Servicio Gallego de Salud (XXIS/SERGAS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of He
  • Feijóo-Bandín S; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago/Servicio Gallego de Salud (XXIS/SERGAS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of He
  • Otero Santiago M; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago/Servicio Gallego de Salud (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Barral L; Group of Polymers, Department of Physics and Earth Sciences, University of La Coruña, Spain.
  • Campos-Toimil M; Group of Pharmacology of Chronic Diseases (CD Pharma), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Spain.
  • Gil-Longo J; Group of Pharmacology of Chronic Diseases (CD Pharma), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Spain.
  • Costa Pereira TM; Group of Pharmacology of Chronic Diseases (CD Pharma), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Spain; Pharmaceutical Sciences Graduate Program, Federal Institute of Education, Science and Technology (IFES), Vila Velha, ES, Brazil.
  • García-Caballero T; Department of Morphological Sciences, University of Santiago de Compostela and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Rodríguez-Segade S; Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Spain; Clinical Biochemistry Laboratory, Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Rodríguez J; Clinical Biochemistry Laboratory, Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • Tarazón E; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Spain; Cardiocirculatory Unit, Health Research Institute of La Fe University Hospital, Valencia, Spain.
  • Roselló-Lletí E; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Spain; Cardiocirculatory Unit, Health Research Institute of La Fe University Hospital, Valencia, Spain.
  • Portolés M; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Spain; Cardiocirculatory Unit, Health Research Institute of La Fe University Hospital, Valencia, Spain.
  • Gualillo O; Laboratory of Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • González-Juanatey JR; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago/Servicio Gallego de Salud (XXIS/SERGAS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of He
  • Lago F; Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research and Xerencia de Xestión Integrada de Santiago/Servicio Gallego de Salud (XXIS/SERGAS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of He
Biochem Pharmacol ; 170: 113677, 2019 12.
Article em En | MEDLINE | ID: mdl-31647926
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autofagia / Compostos Benzidrílicos / Antígenos CD36 / Metabolismo dos Lipídeos / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos / Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Biochem Pharmacol Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autofagia / Compostos Benzidrílicos / Antígenos CD36 / Metabolismo dos Lipídeos / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos / Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Biochem Pharmacol Ano de publicação: 2019 Tipo de documento: Article